Correspondence 0001193125-24-014037 from Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc.
Date: Jan. 24, 2024 · CIK: 0000882361 · Accession: 0001193125-24-014037
AI Filing Summary & Sentiment
File numbers found in text: 333-275870
Letter
Re: Aptose Biosciences Inc.
January 24, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-275870
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as underwriter for the above-referenced offering, hereby join in the request of Aptose Biosciences Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 PM, Eastern Time, on January 25, 2024, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Dorsey & Whitney LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement.
We, the undersigned, as underwriter, have complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
NEWBRIDGE SECURITIES CORPORATION
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 24, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Aptose Biosciences Inc. Registration Statement on Form S-1 File No. 333-275870 Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as underwriter for the above-referenced offering, hereby join in the request of Aptose Biosciences Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 PM, Eastern Time, on January 25, 2024, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Dorsey & Whitney LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the prospectus to underwriters, dealers, institutions and others prior to the requested effective time of the Registration Statement. We, the undersigned, as underwriter, have complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, NEWBRIDGE SECURITIES CORPORATION By: /s/ Chad D. Champion Name: Chad D. Champion Title: Senior Managing Director